|
Thursday, 4 March 2021, 08:12 HKT/SGT | |
| | | | Source: Eisai | |
|
|
TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians. Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people. As the novel coronavirus infection spreads in Kenya, one issue in Meru County is the time required to receive screening results as samples must be sent across over 200 kilometers to the capital city of Nairobi for testing, a situation which is caused by a lack of equipment, facilities and technicians necessary for screening of the novel coronavirus. It is expected that support for this effort will contribute largely to the formation of accurate and rapid understanding of the infection situation as well as strategy that is based on that understanding by construction of PCR testing in Meru County. Eisai has committed the equivalent of 1 million USD in aid over the span of 1 year in order to support the controlling of the spread of the novel coronavirus infection in Africa, along with prevention of delays of elimination activities for neglected tropical diseases (NTDs). As part of this support, Eisai has begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of and countermeasures against infectious diseases, as well as masks and sanitizer for the resuming of mass drug administrations in Kenya for the elimination of NTDs. In addition, Eisai is supporting Amref Health Africa in the development and popularization of its mobile health platform LEAP for healthcare workers in sub-Saharan countries.
Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries. About Connect Afya Co., Ltd. and CA Medlynks Kenya, Ltd.
Connect Afya Co., Ltd. (Headquarters: Hyogo, Japan, CEO: Yoichi Shimada) and its local affiliate CA Medlynks Kenya Ltd. (Location: Nairobi are startups delivering clinical laboratory services and providing in-vitro diagnostic medical equipment, for the realization of a society where people enjoy better lives without suffering from limitations of insufficient medical infrastructure.
As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
Eisai |
July 14, 2025 09:20 HKT/SGT |
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
July 8, 2025 08:31 HKT/SGT |
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment |
June 2, 2025 16:46 HKT/SGT |
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
May 28, 2025 16:45 HKT/SGT |
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
May 21, 2025 14:00 HKT/SGT |
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
May 16, 2025 16:21 HKT/SGT |
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
Apr 30, 2025 13:17 HKT/SGT |
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
Apr 18, 2025 15:52 HKT/SGT |
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
Apr 1, 2025 12:15 HKT/SGT |
Eisai to Divest Rights for Pariet in China to Peak Pharma |
Mar 25, 2025 16:28 HKT/SGT |
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
More news >> |
 |
|
 |
|